Alpine Saxon Woods Capital Return Strategy

Overview

Our Capital Return Strategy focuses on identifying financially sound companies with a demonstrated history of paying and raising dividends alongside meaningful share repurchase programs. We prioritize well-capitalized firms led by management teams committed to growing free cash flow, which supports sustained dividend increases and share buybacks. We carefully evaluate each stock’s current valuation against its historical range and future growth prospects to determine its attractiveness.

‍

Investment Objectives

Our Strategy  focuses on total return through capital appreciation and income. We achieve this by investing in U.S. stocks with high free cash flow that pay dividends and have a meaningful stock repurchase program.

‍

Portfolio Construction

When constructing a portfolio, a disciplined framework guides every investment decision. The process begins with a focus on liquidity, ensuring that only stocks with sufficient trading volume are considered. This provides flexibility and reduces the risk associated with holding illiquid securities.

‍

Each position in the portfolio typically represents 2% to 5% of the total assets, promoting diversification while allowing for conviction in individual ideas. The portfolio usually holds between 30 and 45 securities, striking a balance between concentration and diversification.

‍

To maintain prudent risk exposure, no single security is allowed to comprise more than 10% of the total portfolio. Similarly, sector exposure is carefully managed, generally capped at 25% of the portfolio or 1.5 times the sector’s weight in the benchmark, whichever is greater. This ensures that sector biases do not unduly influence performance.

‍

The portfolio is typically fully invested, reflecting a commitment to staying engaged in the market rather than attempting to time it.

‍

Risk management is an ongoing priority. Quantitative tools are regularly used to review risk statistics, helping to identify where risks exist and in what forms they may be present—whether at the security, sector, or portfolio level. This data-driven approach supports informed decision-making and portfolio resilience through varying market conditions.

Documents

As of

September 30, 2026

Capital Return Strategy Commentary
Capital Return Strategy Factsheet
Capital Return Strategy GIPS Composite Report

Quick Facts

As of

September 30, 2026

Fund
SMA Inception Date
1/1/2019
Benchmark 1
S&P Dividend ETF (SDY)
Benchmark 2
iShares Russell 1000 Value ETF (IWD)
Strategy AUM
$21.41M
Investment Minimum
Negotiable
Fees
Negotiable

Meet the Team

Mark T. Spellman
  • 32 years industry experience
  • BS: Boston College
  • MBA: UMass Amherst
View More
Brian Hennessey, CFA
  • 27 years industry experience
  • BA: Williams College
  • MBA: M.I.T.
View More
Sarah Hunt, CFA, CFP®
  • 26 years industry experience
  • BA: Wesleyan University
  • MBA: Fordham University
View More
Ronak Jain, CFA
  • 17 years industry experience
  • BBA: Macaulay Honor College at Baruch College

‍

View More

Characteristics

As of

September 30, 2026

Strategy
Benchmark 1
Number of Holdings
32
155
Median Market Cap ($B)
100.66
20.48
TTM Dividend Yield
1.58
%
2.98
%
3-Year Dividend Growth
10.24
6.82
5-Year Dividend Growth
10.91
6.3
P/E 1-Year Forward
19.69
17.29
Free Cash Flow Yield
3.87
%
4.3
%
Total Debt/EBITDA
2.22
2.97
Annual Turnover
64.8
–

Sector Analysis

As of

September 30, 2026

Strategy
Benchmark 1
Technology
19.3
%
8.7
%
Financials
16.0
%
12.2
%
Industrials
14.7
%
18.5
%
Healthcare
13.8
%
8.4
%
Consumer Discretionary
8.5
%
5.1
%
Energy
7.5
%
3.7
%
Materials
6.0
%
7.4
%
Consumer Staples
5.3
%
15.9
%
Utilities
4.5
%
12.9
%
Communications
4.4
%
3.2
%
Real Estate
0.0
%
4.0
%

Top 10 Holdings

As of

September 30, 2026

Fund
MICROSOFT CORP
5.6
%
JPMORGAN CHASE
4.6
%
ALPHABET INC-C
4.4
%
PHILLIPS 66
4.3
%
APPLE INC
4.2
%
AMGEN INC
4.0
%
DANAHER CORP
3.9
%
ELI LILLY & CO
3.9
%
NORTHROP GRUMMAN
3.5
%
CHENIERE ENERGY
3.3
%
TOTAL
41.7
%

Risk/Returns Metrics

As of

September 30, 2026

Strategy
Benchmark 1
Alpha
2.30
%
–
Beta
0.85
1.00
Sharpe Ratio
0.40
0.31
Standard Deviation
13.65
%
14.61
%
Up/Down Capture
92/84
–

Average Annual Total Return

As of

September 30, 2026

As of

September 30, 2026

YTD
1 Year
3 Year
5 Year
Since Inception
Gross
11.83
%
12.06
%
15.42
%
9.47
%
12.76
%
Net (Composite)
11.05
%
11.08
%
14.39
%
8.52
%
11.79
%
Benchmark 1
7.24
%
7.33
%
11.26
%
7.28
%
9.49
%
Benchmark 2
19.12
%
23.67
%
19.86
%
11.73
%
13.21
%
YTD
1 Year
3 Year
5 Year
Since Inception
Gross
11.83
%
12.06
%
15.42
%
9.47
%
12.76
%
Net (Composite)
11.05
%
11.08
%
14.39
%
8.52
%
11.79
%
Benchmark 1
7.24
%
7.33
%
11.26
%
7.28
%
9.49
%
Benchmark 2
19.12
%
23.67
%
19.86
%
11.73
%
13.21
%

The Quarter's Top Contributors

As of

June 30, 2026

Semiconductor equipment manufacturer Lam Research (LRCX) is a top contributor for the fourth quarter in a row. AI-related spending and tariff worries evident early in 2025 have all but dissipated and LRCX continued to rise posting strong earnings and order books. We continue to own this well-positioned semiconductor equipment manufacturer and believe the industry is well-positioned on a multi-year basis. Semiconductor manufacturer Texas Instruments (TXN) was also a top contributor as the semiconductor industry enjoyed a large rally during the quarter. Companies like TXN, tied to the build-out for AI computing capacity, reported positive results and order outlooks as the data center build out marches on. Drug maker Eli Lilly (LLY), a position initiated during the quarter, was also a top contributor. The company not only reported better-than-expected results in its GLP-1 franchise of Zepbound and Mounjaro, but also for its newly launched daily pill version called Foundayo. Further boosting the shares were some positive Phase III results for its next-generation GLP-1 drug, retatruide. Investors have also been cheered by LLY’s M&A strategy of investing its +$12B in annual free cash flow into companies with products that will diversify its product line-up. The Company has announced purchases of at least eight companies for nearly $20B this year in treatment areas including narcolepsy, cell therapies to treat certain cancers, and infectious diseases and vaccines.

‍

The Quarter's Top Detractors

As of

June 30, 2026

Defense contractors Northrop Grumman (NOC) and L3Harris Technologies (LHX) both underperformed in the quarter after starting off the year strongly when they benefitted from war in the Middle East. The prospects for the end of hostilities caused weakness in the shares as the market rotated back into AI and technology hardware names. We think the outlook for defense procurement is poised to rise for some time and saw the weakness in the shares as an opportunity to increase our exposure. Near the end of the quarter, we increased our positions in both NOC and LHX. 2Q26 Cheniere Energy (LNG) shares slipped during the quarter after starting the year off strongly with the onset of the Middle East war. Shares of the liquefied natural gas supplier benefited in 1Q26 from higher prices (and were a top contributor) brought on by supply disruptions at other producers’ facilities in the Middle East. By 2Q26, similarly to the defense names mentioned earlier, the shares weakened with the prospects of an end to hostilities and a return of Middle East supplies. We reduced our LNG position early in the quarter as momentum began to lag. We think the longer-term prospects for liquefied natural gas production, pricing, and demand growth remains positive, and LNG shares should continue to benefit in spite of any “outbreak of peace”. We continue to hold shares of LNG.

‍